Corient Private Wealth
HZNP

Corient Private Wealth’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Corient Private Wealth’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,921
Closed -$1.73M – 2382
2023
Q3 		$1.73M Buy
14,921
+1,580
+12% +$170K ﹤0.01% 971
2023
Q2 		$1.37M Sell
13,341
-395
-3% -$41.7K ﹤0.01% 1042
2023
Q1 		$1.5M Buy
13,736
+1,605
+13% +$177K ﹤0.01% 944
2022
Q4 		$1.38M Buy
+12,131
New +$1.01M 0.01% 816

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Corient Private Wealth's HZNP Position: Q4 2023 in Review

Corient Private Wealth sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 14,921 shares — an estimated $1.73M sold.

Corient Private Wealth first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $1.73M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Corient Private Wealth reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Corient Private Wealth sold 14,921 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.73M.
  • Corient Private Wealth first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Corient Private Wealth's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.73M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Corient Private Wealth's 13F filing for Q4 2023, filed 9 Feb 2024.